- POAI’s
artificial intelligence (AI)-driven tumor profiling platform brings
precision medicine tools to clinicians and researchers to improve cancer
outcomes
- The
company holds a critical strategic advantage over mammoth competitors,
attracting investor attention
- POAI
is committed to providing sophisticated tools to help select current
therapies more precisely and develop new targeted therapies
Predictive Oncology Inc. (NASDAQ: POAI) is working
with the pharmaceutical and biotech industries to offer an AI-driven tumor
profiling platform that clinicians and researchers can use to improve outcomes
for cancer patients of today and tomorrow. POAI has built a distinctly valuable
asset in its existing base of drug-response outcome evidence; this data has the
potential to revolutionize the way cancer is treated (http://ibn.fm/M1mcR).
Though seeming like David in the face of Goliath-sized
competition, POAI holds a critical strategic advantage over such mammoth
companies as Foundation Medicine and Tempus; while these competitors must wait
at least five years to find out if the patient survived treatment before they
can show value from their investments in gathering data, POAI’s dataset already
contains large amounts of data going back more than 10 years, allowing it to
build predictive models much more quickly and robustly. By simply analyzing the
tumor it has already banked, Predictive Oncology can combine this with the drug
response data it already has, delivering valuable, actionable insights to
clinicians and researchers in months rather than years.
POAI’s technology combines its database of evidence
documenting actual drug responses of cancer patients’ tumors with artificial
intelligence (AI) to create an invaluable predictive tool for clinicians and
researchers. Predictive Oncology’s data offers a valuable customizable
assessment method that can be used by oncologists to determine the best drug for
fighting a specific patient’s cancer. This disruptive technology is the first
of its kind and is also meeting a critical need in the pharmaceutical,
diagnostic and biotech industries to speed up the search for new precision
therapies by providing tools to better predict how new drugs work on different
cancers (http://ibn.fm/0YnNI).
POAI’s wholly owned subsidiaries – Helomics and TumorGenesis
– are working together to bring these important precision medicine tools to
physicians. “The TumorGenesis platform and its methodology for tagging a
tumor’s diverse cancer cell population is highly complementary to our Helomics
discovery service business, which utilizes AI-driven tumor genetic and drug
response profiling,” POAI CEO Dr. Carl Schwartz stated in a news release (http://ibn.fm/f5o4f). “Our
vision is to tag every patient’s complex tumor cell populations first with
biomarkers, creating a unique ‘fingerprint’ of that tumor to deliver a
personalized medicine approach to cancer treatment.”
Massachusetts-based genetic profiling company Foundation
Medicine, which was taken over by Swiss company Roche in 2018, is continuing to
grow its own dataset on the treatment of patients with cancer. Similarly,
Chicago-based Tempus has worked to sequence patient tumors and is mining
medical records to look for outcomes.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
